Compare US Bancorp (USB) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
US Bancorp vs State Street SPDR S&P Biotech ETF — how do they compare? US Bancorp trades at $57.29 (market cap $88.86B), while State Street SPDR S&P Biotech ETF trades at $153.91 (market cap $10.11B). The key difference: US Bancorp is far larger — about 8.8× State Street SPDR S&P Biotech ETF's market cap, and US Bancorp pays a 3.79% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold US Bancorp for 97 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| USB | XBI | |
|---|---|---|
Market Cap | $88.86B | $10.11B |
Volume | 8,869,993 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $65.42 | $169.55 |
52-Week Low | $45.28 | $104.99 |
Typical Hold Time | 97 Days | 38 Days |
Enterprise Value | $118.35B | — |
Dividend Yield | 3.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
U.S. Bancorp (USB) trades at $56.81, up 1.14% today, but technical indicators are bearish with moving averages signaling a downtrend. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Fundamentals show strong profitability with a 27.61% net income margin and a modest P/E of 11.38. The company recently raised its dividend by 3.8% to $0.54 per share, reflecting confidence in its financial health.
The outlook is mixed: analyst consensus is bullish with a $69.94 price target, but near-term technical weakness and macroeconomic sensitivity pose risks. Upside potential hinges on continued earnings outperformance and stable interest rates, while downside risks include regulatory changes and economic volatility.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
